SV

Street Verdict

Analyst Scorecard

AUROPHARMA · NSE

Aurobindo Pharma Limited

₹1,734

+2.60% (+₹44)

Prev. close

₹1,690

Volume

12,09,478

Delivery %

56.1%

As of

18 Sept 2026

Price history

Bullish

Jay Thakkar · ICICI Securities · 12 Aug 2026

“Recommends buying Aurobindo Pharma Futures in the ₹1,650-1,660 range, targeting ₹1,740-1,780, with a stop loss below ₹1,600. This bullish view is driven by the stock breaking its all-time high levels, accompanied by an increase in open interest, indicating a strong long build-up.”

Entry ₹1,650–₹1,660Target ₹1,740 (+4.8%)Stop ₹1,600 (-3.6%)R:R 1.3:1Stopped out · 21 Aug 2026

Published mid-session at 10:52 IST. Tracking counts only prices printed after publication — the chart's dashed divider marks that moment; earlier prices never count toward entry or results.

Target ₹1,740NOT GRADEDCall pageClear
₹1,734+₹74 (+4.46%) · CALL
12 Aug 2026 → 18 Sept 2026
Target ₹1,740SL ₹1,600Entry ₹1,660Entry zone ₹1,650–₹1,66012 Aug21 Aug01 Sept09 Sept18 SeptCall published 10:52
Jay Thakkar's call · 12 Aug 2026

Analyst sentiment

Analysts lean bullish

2 analyst stances · last 90 days · one per analyst

Trackable

2 · 2 bull / 0 neutral / 0 bear

Long-Horizon

none in window

Commentary

none in window

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (2)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
“Recommends buying Aurobindo Pharma Futures in the ₹1,650-1,660 range, targeting ₹1,740-1,780, with a stop loss below ₹1,…”Jay ThakkarICICI SecuritiesAurobindo PharmaNOT GRADED
“Recommends buying Aurobindo Pharma Futures in the ₹1,650-1,660 range, targeting ₹1,740-1,780, with a stop loss below ₹1,600. This bullish view is driven by the stock breaking its all-time high levels, accompanied by an increase in open interest, indicating a strong long build-up.”
Trade setupTarget ₹1,740Track opinion →

This call couldn't be objectively graded against market data.

Read the original article

Fundamentals

About Aurobindo Pharma Limited

Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas. It also provides ointments, creams, gels, powders, transdermal, and lotions; antiretroviral drugs for PLHIV & CLHIV; and injectable products, including Penems, Penicillin, Cephalosporin, ophthalmic, inhalation, oncology, and hormone products. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Dr. Makkapati Satakarni B.E., M.B.A., Ph.D.

Headquarters

Hyderabad

Employees

29,209

Key stats

Market cap

₹99,770.53 Cr

P/E ratio (TTM)

27.1

Dividend yield

0.24%

EPS (TTM)

₹64.05

Beta (1Y · daily vs NIFTY 50)

0.35

Beta (5Y · monthly vs NIFTY 50)

0.91

Shares float

27.61 Cr

EPS · quarter ended Jun 2026

₹17.86

Upcoming earnings

05 Nov 2026

Financial Performance

01 · Financials

0 Cr10000 Cr20000 Cr30000 Cr40000 Cr₹-10%0%10%20%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDARevenue growth YoY

FY21 growth needs FY20 filings, which the data source doesn't provide.

02 · Earnings Per Share (EPS)

0255075100₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

0246₹-100%-50%0%50%100%17 Feb 2021 Aug 2023 Nov 2022 Feb 2127 Aug 2117 Nov 2118 Feb 2206 Jun 2217 Feb 2320 Nov 2320 Feb 2408 Aug 25
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-20%0%20%40%FY21FY22FY23FY24FY25FY26
SalesFixed assetsReceivables (trade + unbilled)Inventory

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr20000 Cr40000 Cr60000 Cr₹0×0.2×0.4×0.6×0.8×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr20000 Cr40000 Cr60000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

-5000 Cr0 Cr5000 Cr10000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹24,774.63 Cr₹23,455.49 Cr₹24,855.38 Cr₹29,001.87 Cr₹31,723.73 Cr₹33,653.08 Cr
EBITDA₹8,528.83 Cr₹4,579.15 Cr₹4,009.23 Cr₹6,139.99 Cr₹7,097.88 Cr₹7,272.49 Cr
₹5,335.00 Cr₹2,648.15 Cr₹1,927.50 Cr₹3,172.97 Cr₹3,485.88 Cr₹3,504.75 Cr
Diluted EPS₹91.04₹45.19₹32.9₹54.16₹59.81₹60.34

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹33,853.99 Cr₹33,921.72 Cr₹39,505.00 Cr₹44,717.00 Cr₹49,482.00 Cr₹58,196.00 Cr
₹5,339.08 Cr₹2,851.27 Cr₹5,286.21 Cr₹6,647.63 Cr₹8,262.87 Cr₹8,072.84 Cr
Stockholders' equity₹21,929.87 Cr₹24,575.98 Cr₹26,840.00 Cr₹29,843.00 Cr₹32,653.00 Cr₹37,891.00 Cr

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹3,328.92 Cr₹5,016.48 Cr₹2,387.00 Cr₹2,435.00 Cr₹3,925.00 Cr₹5,526.00 Cr
Investing cash flow₹598.69 Cr₹-3,214.81 Cr₹-3,977.75 Cr₹-4,255.95 Cr₹-1,875.14 Cr₹-3,458.43 Cr
₹-1,364.81 Cr₹-2,969.27 Cr₹1,814.00 Cr₹800.00 Cr₹120.00 Cr₹-1,269.00 Cr
Capital expenditure₹-1,873.81 Cr₹-2,704.64 Cr₹-2,720.00 Cr₹-3,562.00 Cr₹-2,520.00 Cr₹-3,105.00 Cr
End cash position₹5,373.47 Cr₹4,162.51 Cr₹4,392.27 Cr₹3,385.43 Cr₹5,563.79 Cr₹7,191.40 Cr

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21–Mar 24(11Q)Jun 24Sep 24–Mar 26(7Q)Jun 26
Promoter51.83%51.80%51.82%51.88%
Public48.17%48.20%48.18%48.12%
Employee trusts0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.48 L Cr₹1,837.337.05.3613.7%0.06+11.9%+11.4%
Divi's Laboratories Limited₹2.47 L Cr₹9,37583.314.7715.3%0.00+12.3%+53.4%
Torrent Pharmaceuticals Limited₹1.83 L Cr₹4,87576.921.8225.8%1.79+21.5%+37.4%
Apollo Hospitals Enterprise Limited₹1.26 L Cr₹8,944.560.413.3020.5%0.90+15.7%+13.9%
Lenskart Solutions Limited₹1.18 L Cr₹707.2179.913.485.6%0.35+35.4%—
Zydus Lifesciences Limited₹1.13 L Cr₹1,16025.34.1818.6%0.46+18.4%+10.7%
Cipla Limited₹1.10 L Cr₹1,376.332.53.1911.3%0.02+2.1%-11.8%
Laurus Labs Limited₹1.05 L Cr₹1,95496.419.8616.8%0.48+22.0%+111.6%
Max Healthcare Institute Limited₹1.01 L Cr₹1,049.369.89.3913.4%0.32+19.0%-10.6%
Dr. Reddy's Laboratories Limited₹97,876.16 Cr₹1,18529.62.6011.4%0.21+3.2%-10.4%
Manipal Health Enterprises Limited₹97,364.22 Cr₹738.95146.611.567.8%1.53+18.0%—
Aurobindo Pharma Limited₹97,238.87 Cr₹1,73426.42.579.2%0.21+6.4%+53.6%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Annual reports

Show all 30

Concall transcripts

Show all 12

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

Index membership

45 indices

Nifty MidSmall Healthcare· 7.2%Nifty Pharma· 4.8%Nifty Healthcare· 4.2%Nifty Midcap Select· 3.5%BSE MidCap Select Index· 3.4%Nifty500 Healthcare· 3.3%BSE Healthcare· 2.9%Nifty Midcap150 Momentum 50· 2.4%Nifty Midcap 50· 2.1%Nifty MidSmallcap400 Momentum Quality 100· 2.0%Nifty Midcap 100· 1.4%BSE LargeMid (60:40) Stable Dividend 50· 1.3%

NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.

AUROPHARMA

JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?

The Economic Times · 3 days ago

AUROPHARMA

Aurobindo Pharma shares fall 2% after USFDA issues one observation for Telangana facility

Moneycontrol.com · 3 days ago